Insulet Reports Strong Q3 2026 Results with 19.6% Revenue Growth
Insulet (PODD) delivered a robust third quarter for 2026, reporting total revenue of $842.0 million, which represents a 19.6% increase in constant currency and exceeded the company's previous guidance. Adjusted earnings per share rose significantly by 59.9% year-over-year to $1.99, supported by an adjusted operating margin expansion of 490 basis points to 22.0%. The company's global customer base surpassed 600,000, driven by steady demand in both US and international markets. While the current quarter showed strong momentum, management provided a more conservative outlook for 2027, projecting revenue growth in the low teens due to a larger scale and increased competition. Key future catalysts include the planned launch of Omnipod 6 in 2027 and a target 510(k) submission for a Type 2 fully closed-loop system in 2027. To reward shareholders, the board approved an additional $1 billion for share repurchases.
Tickers: $PODD
Topics: diabetes care market eps beat operating margin revenue growth